Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

WHO approves Sinovac COVID shot in second Chinese milestone

Published 06/01/2021, 12:31 PM
Updated 06/02/2021, 12:55 AM
© Reuters. FILE PHOTO: A medical worker holds a dose of the Sinovac vaccine at a district health facility as Indonesia begins mass vaccination for the coronavirus disease (COVID-19), starting with its healthcare workers, in Jakarta, Indonesia January 14, 2021. REUTE

© Reuters. FILE PHOTO: A medical worker holds a dose of the Sinovac vaccine at a district health facility as Indonesia begins mass vaccination for the coronavirus disease (COVID-19), starting with its healthcare workers, in Jakarta, Indonesia January 14, 2021. REUTE

By Stephanie Nebehay

GENEVA (Reuters) -The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in poor countries.

A WHO emergency listing is a signal to national regulators of a product's safety and efficacy and will allow the Sinovac shot to be included in COVAX, the global programme providing vaccines mainly for poor countries, which faces major supply problems due to curbs on Indian exports.

The WHO's independent panel of experts said in a statement it recommended Sinovac's vaccine for adults over 18. There was no upper age limit as data suggested it is likely to have a protective effect in older people.

The WHO's technical advisory group, which began meeting on May 5, made the decision after reviewing the latest clinical data on the Sinovac vaccine's safety and efficacy as well as the company's manufacturing practices.

WHO Director-General Tedros Adhanom Ghebreyesus welcomed the move, calling the vaccine safe and effective and noting its easy storage requirements make it suitable for low-income countries.

"It's now crucial to get these lifesaving tools to the people that need them quickly," he told a briefing.

Branded CoronaVac in some regions, it is the eighth vaccine to win such a WHO listing to combat COVID-19 and the second developed by a Chinese company, after the May 7 approval of a shot developed by state-backed Sinopharm.

While a third Chinese vaccine, produced by CanSino Biologics, has submitted clinical trial data, no WHO review has been scheduled.

Sinovac said that it had supplied more than 600 million doses of its vaccine at home and abroad as of end-May and over 430 million doses have been administered.

BIG BOOST

The endorsement is a big boost for Sinovac's vaccine after data in clinical trials showed a wide range of efficacy rates.

The WHO said results showed it prevented symptomatic disease in 51% of those vaccinated and prevented severe COVID-19 and hospitalisation in 100% of the studied population.

The WHO's separate Strategic Advisory Group of Experts (SAGE) had said previously that vaccine efficacy in multi-country Phase III clinical trials ranged from 51% to 84%.

Indonesia said on May 12 that its study of 120,000 healthcare workers who had received the vaccine found it was 94% effective at preventing symptomatic disease.

In a preliminary evaluation, the SAGE panel found that the shot was effective in preventing COVID-19 in adults under 60, but that some quality data on the risk of serious adverse effects was lacking.

It cited evidence gaps in safety in pregnancy, and on safety and clinical protection in older adults, those with underlying disease, and evaluation of rare adverse events.

SAGE experts, who issue policy recommendations to states and dosage guidelines, reviewed Sinovac clinical data last month.

© Reuters. FILE PHOTO: A medical worker holds a dose of the Sinovac vaccine at a district health facility as Indonesia begins mass vaccination for the coronavirus disease (COVID-19), starting with its healthcare workers, in Jakarta, Indonesia January 14, 2021. REUTERS/Willy Kurniawan

Sinovac chairman and chief executive Weidong Yin said in a statement that clinical trials had provided a "solid scientific foundation" for the drugmaker's shot to be approved by more than 40 countries and by the WHO.

China has already deployed hundreds of millions of doses of both Sinopharm and Sinovac vaccines at home and exported them to many countries, particularly in Africa, Asia and Latin America.

Latest comments

I told you guys... China's vaccine will be the best. I am waiting for that one to come here...
Based on you professional medical opinion? Or just a blind loyalty to something you don't understand? Anyhow, you are entitled to your opinion and your body is your to do as you will.
The first milestone was spreading virus out Wuhan with help from Dr Fauci
Virus out of Wuhan is correct. Dr Fauci spreading the virus is akin to saying the tooth fairy is working some black op for a shady government department. Stick to the meds bro, otherwise the men in white coats are coming to return you back to the cray cray ranch.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.